Medication info

Abifure Tablet 5/20 Milligrams

Prescription medicationTabletOralExpired
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tablet
Manufacturer / importer
Taekuk Pharmaceutical Co., Ltd.
Appearance
White round film-coated tablet
Packaging
30 tablets (10 tablets/PTP × 3)
Approval status
Expired

MFDS item code 201906397 · Approved 2019.09.10

This product's status changed to Expired on 2024.09.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medication, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medication may be considered. The maximum dose of this medication is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into account. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. This medication is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive medications and/or diuretics. This medication should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not be administered this medication under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient’s renal or cardiac function and comorbid conditions. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
∘Pediatric patients: The safety and efficacy of this medication have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Taekuk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication can be used to effectively manage blood pressure when blood pressure is not sufficiently controlled with either amlodipine or olmesartan medoxomil alone in patients with essential hypertension. This treatment helps prevent cardiovascular complications and improves the patient's overall health. Therefore, it aids in the stable management of blood pressure in hypertensive patients who have difficulty controlling their blood pressure.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medication, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medication may be considered. The maximum dose of this medication is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into account. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. This medication is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive medications and/or diuretics. This medication should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not be administered this medication under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient’s renal or cardiac function and comorbid conditions. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

∘Pediatric patients: The safety and efficacy of this medication have not been established in pediatric patients under 18 years of age.

Precautions

This medication may cause serious harm to the fetus and newborn if taken during the second and third trimester of pregnancy, so if pregnancy is confirmed, it should be stopped immediately. This medication should not be taken by individuals who are allergic to the active ingredients or similar medications, those who are pregnant or breastfeeding, patients with severe liver impairment, aortic stenosis, biliary obstruction, those undergoing renal dialysis, patients in shock, and certain diabetic patients. Patients with fluid or salt depletion, those with vasodilation, impaired cardiac or renal function, and individuals with liver dysfunction should exercise extreme caution while using this medication and should be closely monitored. This drug can cause various side effects, including dizziness, headache, hypotension, palpitations, indigestion, rash, and swelling; if any abnormal symptoms occur, consult a healthcare professional immediately. This medication may interact with other antihypertensive drugs or certain medications, so any currently taken medications should be disclosed to a doctor or pharmacist. It is safest not to use this drug during pregnancy, especially in the second and third trimesters, as it can cause serious harm to the fetus; therefore, women planning pregnancy or who are pregnant should not take this drug. If breastfeeding, since this drug can be passed into breast milk, one should consult with a doctor about whether to continue breastfeeding or stop taking the medication. It is not recommended for use in children under the age of 18, as its safety and efficacy have not been established in this population. Elderly patients may have diminished kidney and liver function; therefore, starting at a lower dose and careful monitoring is advised. In case of overdose, severe hypotension or symptoms due to vasodilation may occur, necessitating immediate hospital treatment for appropriate care. This medication should be stored in a sealed container to protect it from light and moisture, and should be kept out of reach of children; it is best not to transfer it to another container.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • hypoesthesia
  • syncope
Show 80 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • lumbago
  • nocturia
  • erectile dysfunction
  • peripheral edema
  • edema
  • dependent edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gum bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • diplopia
  • insomnia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is important to maintain the storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

30 tablets (10 tablets/PTP × 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.